This single-centre retrospective cohort included 413 operable breast cancer patients treated with neoadjuvant chemotherapy (NACT) between January 2013 and November 2020. The cohort ranged from cT1 to cT3 and from cN0 to cN3, with a median age reported as 51. Investigators reported overall pathological response concordance between the breast and axilla of 81%; that comprised 22.2% with both breast and axillary pathological complete response (breast pCR and axillary pCR) and 58.8% with concurrent residual disease. Short statement: concordance was common.
The authors separated outcomes by clinical nodal status. In the clinically node-negative (cN0) subgroup, achieving breast pCR correlated with a markedly higher ypN0 rate: 97.1% when the breast reached pCR versus 80.8% when it did not (p<0.001). For clinically node-positive (cN+) patients, breast pCR was again linked to higher rates of axillary clearance; by contrast, only 16.5% of cN+ patients with residual breast disease achieved axillary pCR. The source did not provide granular imaging or pathological criteria beyond these reported figures.
The study team used logistic regression to identify predictors of complete axillary response. They reported that breast pCR was the most significant predictor of axillary pCR (odds ratio 11.6, p<0.001). This result formed the core statistical signal supporting correlation between primary tumour response and nodal clearance.
Subtype-specific rates of axillary pCR were reported. The highest axillary pCR proportion was in ER-/HER2+ tumours at 66.7%, followed by triple-negative disease at 46.9%. The authors presented these subtype differences without additional breakdown of endocrine receptor percentages or HER2 testing methodology in the text provided. No dosing regimens, specific chemotherapy agents, or number of cycles were described in the source material.
Using Cox proportional hazards regression, the investigators explored associations between residual axillary disease and survival outcomes. Residual nodal involvement was independently associated with worse breast cancer–specific survival (hazard ratio 7.13, p=0.006) and worse overall survival (hazard ratio 3.32, p=0.029), according to the source. Kaplan–Meier analyses supplied by the authors showed a trend toward poorer survival for patients with axillary residual disease, a pattern that persisted even among the subset of patients who achieved breast pCR. The study did not, however, report specific event counts, median follow-up time, or absolute survival percentages in the abstract and text available here.
The cohort data strengthen an argument for selective axillary de-escalation when the breast achieves pathological complete response after NACT, particularly in biologic subtypes that showed higher axillary pCR rates (ER-/HER2+ and triple-negative). The authors proposed that careful post-NACT assessment could inform less invasive axillary management in selected patients. They did not, in the report provided, specify precise selection algorithms, imaging thresholds, or prospective protocols for omitting axillary surgery; such operational details were not included in the source text.
Clinical teams considering de-escalation will need to integrate these observational correlations with surgical judgement, nodal staging accuracy, and multidisciplinary risk assessment. The logistic regression signal (OR=11.6) suggests a strong association, but an observational study cannot define causal thresholds for changing standard nodal management.
The authors described this work as a limited single-centre series and framed the findings accordingly. The source did not provide detailed chemotherapy regimens, radiological response criteria, or granular follow-up durations in the publicly available text. Ethical oversight was addressed: the IRB (Patient Outcomes Team or Audit Team) of Cambridge University Hospitals waived formal ethical approval, classifying the work as a service evaluation/clinical audit. Individual patient consent was not required, per the authors’ declaration.
Data used in the analysis are available from the authors on reasonable request, subject to institutional approval, the source noted. The report makes no claim about changing clinical standards; instead, investigators argued for stratified approaches to axillary de-escalation informed by post-NACT assessment and tumour biology. Remaining unanswered questions include prospective validation of selection criteria, the optimal non-operative nodal assessment strategy after NACT, and how these associations perform across varied treatment protocols—none of which were detailed in the source text.